세계의 폐쇄형 수술 후 배액 시장 전망(-2030년)

Cardinal Health (US), Zimmer Biomet (US), Axiom Medical, Inc. (US), Angiplast Pvt. Ltd. (India), Polymedicure (India), Becton, Dickinson, and Company (US), Braun SE (Germany), StayGuard (US), Medline Industries, Inc. (US), and VariVac International Medical Research Pty Ltd. (Australia), Ingelheim (Ingelheim am Rhein, Germany), Vetoquinol (Lure, France), Ceva Animal Health, LLC (Libourne, France), Chanelle Pharma (Galway, Ireland), Elanco (Indiana, US), SOMAVAC Medical Solutions, Inc. (US).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENCE OF CHRONIC WOUNDS AND SURGICAL SITE INFECTIONS
  • 4.2.2 RISING PREVALENCE OF CHRONIC DISEASES
  • 4.2.3 RISING AWARENESS ABOUT THE BENEFITS OF CLOSED SURGICAL WOUND DRAINAGE AND TECHNOLOGICAL ADVANCEMENTS
• 4.3 RESTRAINTS
  • 4.3.1 INCREASING CONCERNS OVER SIDE EFFECTS
  • 4.3.2 RISE IN THE NUMBER OF MINIMALLY INVASIVE SURGERIES
• 4.4 OPPORTUNITIES
  • 4.4.1 GROWING AGING POPULATION

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D & DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET
  • 5.3.1 IMPACT ON MARKET GROWTH
  • 5.3.2 DEMAND SUPPLY ANALYSIS
  • 5.3.3 IMPACT ON KEY PLAYERS
• 5.4 REIMBURSEMENT SCENARIO FOR CLOSED SURGICAL WOUND DRAINAGE
  • 5.4.1 REIMBURSEMENT SCENARIO BY COUNTRY

6 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 CLOSED SURGICAL DRAINAGE SYSTEMS
• 6.3 ACCESSORIES

7 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY TYPE

• 7.1 OVERVIEW
• 7.2 ACTIVE DRAINS
• 7.3 PASSIVE DRAINS

8 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY AGE GROUP

• 8.1 OVERVIEW
• 8.2 ADULT
• 8.3 PAEDIATRIC

9 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY APPLICATION

• 9.1 OVERVIEW
• 9.2 GENERAL SURGERY
• 9.3 ORTHOPEDICS SURGERY
• 9.4 CARDIAC & THORACIC SURGERY
• 9.5 OBSTETRIC/GYNECOLOGICAL SURGERY
• 9.6 OTHERS

10 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY END USER

• 10.1 OVERVIEW
• 10.2 HOSPITALS & CLINICS
• 10.3 AMBULATORY SURGICAL CENTERS
• 10.4 OTHERS

11 GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET, BY REGION

• 11.1 OVERVIEW
• 11.2 NORTH AMERICA
  • 11.2.1 US
  • 11.2.2 CANADA
• 11.3 EUROPE
  • 11.3.1 GERMANY
  • 11.3.2 FRANCE
  • 11.3.3 UK
  • 11.3.4 ITALY
  • 11.3.5 SPAIN
  • 11.3.6 REST OF EUROPE
• 11.4 ASIA-PACIFIC
  • 11.4.1 CHINA
  • 11.4.2 INDIA
  • 11.4.3 JAPAN
  • 11.4.4 SOUTH KOREA
  • 11.4.5 AUSTRALIA
  • 11.4.6 REST OF ASIA-PACIFIC
• 11.5 REST OF THE WORLD
  • 11.5.1 AFRICA
  • 11.5.2 LATIN AMERICA
  • 11.5.3 MIDDLE EAST

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 COMPETITIVE BENCHMARKING
• 12.3 MAJOR GROWTH STRATEGY IN THE GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET
• 12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL CLOSED SURGICAL WOUND DRAINAGE MARKET
• 12.5 FINANCIAL MATRIX
  • 12.5.1 SALES (USD MILLION), 2022
  • 12.5.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022

13 COMPANY PROFILES

• 13.1 CARDINAL HEALTH
  • 13.1.1 COMPANY OVERVIEW
  • 13.1.2 FINANCIAL OVERVIEW
  • 13.1.3 PRODUCTS OFFERED
  • 13.1.4 KEY DEVELOPMENTS
  • 13.1.5 SWOT ANALYSIS
  • 13.1.6 KEY STRATEGIES
• 13.2 ZIMMER BIOMET
  • 13.2.1 COMPANY OVERVIEW
  • 13.2.2 FINANCIAL OVERVIEW
  • 13.2.3 PRODUCTS OFFERED
  • 13.2.4 KEY DEVELOPMENTS
  • 13.2.5 SWOT ANALYSIS
  • 13.2.6 KEY STRATEGIES
• 13.3 AXIOM MEDICAL, INC
  • 13.3.1 COMPANY OVERVIEWS
  • 13.3.2 FINANCIAL OVERVIEW
  • 13.3.3 PRODUCTS OFFERED
  • 13.3.4 KEY DEVELOPMENTS
  • 13.3.5 KEY STRATEGIES
• 13.4 ANGIPLAST PVT. LTD
  • 13.4.1 COMPANY OVERVIEW
  • 13.4.2 FINANCIAL OVERVIEW
  • 13.4.3 PRODUCTS OFFERED
  • 13.4.4 KEY DEVELOPMENTS
  • 13.4.5 KEY STRATEGIES
• 13.5 POLYMEDICURE
  • 13.5.1 COMPANY OVERVIEW
  • 13.5.2 FINANCIAL OVERVIEW
  • 13.5.3 PRODUCTS OFFERED
  • 13.5.4 KEY DEVELOPMENTS
  • 13.5.5 KEY STRATEGIES
• 13.6 BECTON, DICKINSON AND COMPANY
  • 13.6.1 COMPANY OVERVIEW
  • 13.6.2 FINANCIAL OVERVIEW
  • 13.6.3 PRODUCTS OFFERED
  • 13.6.4 KEY DEVELOPMENTS
  • 13.6.5 SWOT ANALYSIS
  • 13.6.6 KEY STRATEGIES
• 13.7 B. BRAUN SE
  • 13.7.1 COMPANY OVERVIEW
  • 13.7.2 FINANCIAL OVERVIEW
  • 13.7.3 PRODUCTS OFFERED
  • 13.7.4 KEY DEVELOPMENTS
  • 13.7.5 SWOT ANALYSIS
  • 13.7.6 KEY STRATEGIES
• 13.8 STAYGUARD
  • 13.8.1 COMPANY OVERVIEW
  • 13.8.2 PRODUCTS OFFERED
  • 13.8.3 KEY DEVELOPMENTS
  • 13.8.4 KEY STRATEGIES
• 13.9 MEDLINE INDUSTRIES, INC
  • 13.9.1 COMPANY OVERVIEW
  • 13.9.2 FINANCIAL OVERVIEW
  • 13.9.3 PRODUCTS OFFERED
  • 13.9.4 KEY DEVELOPMENTS
  • 13.9.5 SWOT ANALYSIS
  • 13.9.6 KEY STRATEGIES
• 13.10 VARIVAC INTERNATIONAL MEDICAL RESEARCH PTY LTD
  • 13.10.1 COMPANY OVERVIEW
  • 13.10.2 FINANCIAL OVERVIEW
  • 13.10.3 PRODUCTS OFFERED
  • 13.10.4 KEY DEVELOPMENTS
  • 13.10.5 KEY STRATEGIES

14 APPENDIX

• 14.1 REFERENCES
• 14.2 RELATED REPORTS